Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23168669 | 0.87 | MAPT (0.44) | KMT2AMAPTALDH1A1MEN1NPSR1 | |
| SCHEMBL24819268 | 0.83 | KMT2A (0.46) | KMT2AMAPTALDH1A1MEN1NPSR1 | |
| SCHEMBL23168750 | 0.80 | MET (0.45) | KMT2AMAPTALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL23168782 | 0.77 | FAAH (0.41) | MAPT | |
| SCHEMBL23168767 | 0.75 | THRA (0.58) | KMT2AMAPTALDH1A1MEN1HTT | |
| SCHEMBL24820997 | 0.75 | MAPT (0.38) | MAPTHTT | |
| SCHEMBL24822266 | 0.75 | PTGS2 (0.40) | MAPTALDH1A1SMN1; SMN2LMNATSHR | |
| SCHEMBL24821005 | 0.74 | MAPT (0.35) | MAPT | |
| SCHEMBL24600370 | 0.72 | SMN1; SMN2 (0.42) | KMT2AMAPTALDH1A1MEN1NPSR1 | |
| SCHEMBL10642406 | 0.68 | HTT (0.58) | KMT2AMAPTALDH1A1MEN1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617769-B2 | Chemical compound as thyroid hormone beta receptor agonist and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| US-20220411400-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-12-29 | — | — | US | disclosed |
| US-20220411400-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-12-29 | — | — | US | disclosed |
| EP-4036090-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2022-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411400-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | THRB, TSHR, THRA | KMT2A 2737/4885MAPT 1873/4885ALDH1A1 1134/4885 |
| US-12617769-B2 | Chemical compound as thyroid hormone beta receptor agonist and use thereof | THRB, TSHR, THRA | KMT2A 4017/4885MAPT 2264/4885ALDH1A1 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.